Kaigene reports $55 million in equity securities sold
The autoimmune drug developer disclosed 22 investors against a $73.35 million offering target.
Kaigene reported $54,958,229 in equity securities sold to 22 investors in a Form D filed on October 14, 2026. The offering began on September 30.
Another $18,391,771 remained against the $73.35 million target. The notice does not identify the subscribers or a named venture stage. The equity financing is separate from commercial licensing and milestone agreements.
The Rockville, Maryland biotechnology company develops antibody medicines for autoimmune diseases. Its research targets harmful antibodies and the mechanisms that sustain their production.